Volitionrx Ltd Up 10.53% To $0.80 After Earnings Meet

Tuesday, March 26, 2024 - Volitionrx Ltd (VNRX) reported in line earnings and downside revenues.

The consensus among analysts for Volitionrx Ltd was for an earnings per share (EPS) loss of $0.11 per share. The firm failed to meet those projections, reporting an EPS loss of $0.11 per share, a neutral surprise of $0. Profits rose 15% year-over-year after reporting an EPS loss of $0.13 per share in its year-ago quarter. The positive growth rate signals that the Healthcare company is performing well amid recent economic conditions.

Consensus analyst estimates were at $450 thousand. The Healthcare company missed on those expectations for its fourth quarter with revenue of $244 thousand, a negative revenue surprise of $206 thousand (46%). The firm managed 104% growth year-over-year due to Volitionrx Ltd reporting quarterly revenue of $119.7 thousand in its year-ago quarter. Volitionrx Ltd achieved a lower earnings growth rate than revenue, signaling that the business has not been able to improve its profit margin.

The stock is up 10.53% to $0.80 after the report.

The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease.

The average recommendation from Wall Street analysts was a Strong Buy which may get revised based on this new data.

Trading in the five days leading up to the report earned Volitionrx Ltd a Bearish Sentiment Rank from InvestorsObserver.

Prior to the report, InvestorsObserver gave the stock an overall score of 43. Meanwhile, the average Wall Street analyst rated the stock a Strong Buy.

VolitionRX Ltd is a us-based multi-national life sciences company. It is engaged in developing easy to use blood-based tests to accurately diagnose a range of cancers. The development pipeline includes assays to be used for symptomatic patients or asymptomatic populations. The company has developed more than 30 blood-based assays to detect specific biomarkers. It also develops Nucleosomics tests for several major cancers including CRC, pancreatic, lung and aggressive prostate. In addition, the company engages in the process of developing HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to help decide the appropriate therapy.